原发性和转移性癌症患者中18F标记活性位点抑制型凝血因子VII(18F-ASIS)靶向组织因子的首次人体PET显像:作为伴随诊断的潜力
本首次人体试验纳入10例癌症患者(胰腺癌4例、乳腺癌3例、肺癌2例、宫颈癌1例),行18F-ASIS PET/CT显像,主要目的为确定安全性、生物分布、药代动力学和剂量学。18F-ASIS给药安全,未观察到不良事件;肿瘤SUVmax与离体组织因子表达呈正相关趋势(r=0.84,P=0.08,n=5)。结论认为18F-ASIS可安全用于癌症患者组织因子表达的PET显像,是组织因子靶向PET示踪剂首次人体试验。
要点
- 18F-ASIS给药安全,未观察到不良事件,生命体征、心电图和血液参数无临床显著变化。
- 200 MBq 18F-ASIS注射活度下全身有效剂量为4 mSv,未发现禁止性器官特异性吸收剂量。
- 肿瘤SUVmax与离体组织因子表达呈正相关趋势(r=0.84,P=0.08,n=5)。
核心结论
- 18F-ASIS可安全用于癌症患者组织因子表达的PET显像。
- 该试验是组织因子靶向PET示踪剂首次在人体中测试(first-in-class)。
- 研究结果为18F-ASIS PET显像组织因子表达的临床实施迈出重要第一步。
研究设计与样本
- 首次人体试验纳入10例癌症患者(胰腺癌4例、乳腺癌3例、肺癌2例、宫颈癌1例)行18F-ASIS PET显像。
- 18F-ASIS平均给药活度为157 ± 35 MBq(范围93-198 MBq)。
- 注射后1、2和4小时行PET/CT;主要目标为确定安全性、生物分布、药代动力学和剂量学。
- 次要目标包括PET定量测量肿瘤组织SUV,以及评估肿瘤SUVmax与离体组织因子表达之间的相关性(Pearson相关)。
主要发现
- 18F-ASIS给药安全,未观察到不良事件;注射后生命体征、心电图或血液参数无临床显著变化。
- 18F-ASIS平均血浆半衰期为3.2 ± 0.6小时,示踪剂主要经尿液排泄。
- 200 MBq 18F-ASIS注射活度下全身有效剂量为4 mSv,未发现禁止性器官特异性吸收剂量。
- 在不同患者之间及肿瘤内部观察到异质性示踪剂摄取。
- 肿瘤SUVmax与离体组织因子表达呈正相关趋势(r=0.84,P=0.08,n=5)。
局限性
- 肿瘤SUVmax与离体组织因子表达的相关性分析样本量小(n=5),P=0.08未达统计学显著。
- 研究结论指出该试验结果为18F-ASIS PET显像组织因子表达临床实施的重要第一步。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tissue factor (TF) expression in cancers correlates with poor prognosis. Recently, the first TF-targeted therapy was approved by the U.S. Food and Drug Administration for cervical cancer. To unfold the potential of TF-targeted therapies, correct stratification and selection of patients eligible for treatments may become important for optimization of patient outcomes. TF-targeted PET imaging based on 18F-radiolabeled active-site inhibited versions of the TF natural ligand coagulation factor VII (18F-ASIS) has in preclinical models convincingly demonstrated its use for noninvasive quantitative measurements of TF expression in tumor tissue. 18F-ASIS PET imaging thus has the potential to act as a diagnostic companion for TF-targeted therapies in the clinical setting. Methods: In this first-in-humans trial, we included 10 cancer patients (4 pancreatic, 3 breast, 2 lung, and 1 cervical cancer) for 18F-ASIS PET imaging. The mean and SD of administered 18F-ASIS activity was 157 ± 35 MBq (range, 93-198 MBq). PET/CT was performed after 1, 2, and 4 h. The primary objectives were to establish the safety, biodistribution, pharmacokinetics, and dosimetry of 18F-ASIS. Secondary objectives included quantitative measurements of SUVs in tumor tissue with PET and evaluation of the correlation (Pearson correlation) between tumor SUVmax and ex vivo TF expression in tumor tissue. Results: Administration of 18F-ASIS was safe, and no adverse events were observed. No clinically significant changes in vital signs, electrocardiograms, or blood parameters were observed after injection of 18F-ASIS. Mean 18F-ASIS plasma half-life was 3.2 ± 0.6 h, and the radiotracer was predominantly excreted in the urine. For injection activity of 200 MBq of 18F-ASIS, effective whole-body dose was 4 mSv and no prohibitive organ-specific absorbed doses were found. Heterogeneous radiotracer uptake was observed across patients and within tumors. We found a trend of a positive correlation between tumor SUVmax and ex vivo TF expression (r = 0.84, P = 0.08, n = 5). Conclusion: 18F-ASIS can be safely administered to cancer patients for PET imaging of TF expression in tumors. The trial marks the first test of a TF-targeted PET radiotracer in humans (first-in-class). The findings represent important first steps toward clinical implementation of 18F-ASIS PET imaging of TF expression.
引用
- Loft M, Christensen C, Clausen MM, et al. First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic. J Nucl Med. 2022. PMID: 35589407. doi:10.2967/jnumed.122.264068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。